文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

COAPT试验:继发性二尖瓣反流经导管缘对缘修复后的超声心动图结局

Echocardiographic Outcomes After Transcatheter Leaflet Approximation in Patients With Secondary Mitral Regurgitation: The COAPT Trial.
PubMed 文献 · J Am Coll Cardiol · 2019-09-28

COAPT试验纳入614例心衰合并中重度(3+)或重度(4+)继发性二尖瓣反流患者,随机接受经导管二尖瓣缘对缘修复(TMVr)联合最大耐受指南导向药物治疗(GDMT)或单纯GDMT。TMVr在各超声心动图亚组中一致获益,独立于左室功能不全、左室扩大、肺动脉高压、三尖瓣反流严重程度或二尖瓣反流特征;随访中两组左室射血分数下降、左室容积增加,但TMVr组变化较小(p<0.05)。

要点

  • 严格超声心动图标准筛选的3+或4+继发性二尖瓣反流心衰患者可从TMVr获益。
  • TMVr获益在各超声心动图亚组中一致,独立于左室功能、左室扩大、肺动脉高压等。
  • 随访2年两组左室射血分数下降、左室容积增加,TMVr组变化较小。

核心结论

  • 严格超声心动图标准筛选的3+或4+继发性二尖瓣反流心衰患者,TMVr可降低2年死亡和心衰住院率。
  • TMVr的获益在所有超声心动图亚组中一致,独立于左室功能不全、左室扩大、肺动脉高压、三尖瓣反流严重程度或二尖瓣反流特征。

研究设计与样本

  • COAPT试验随机对照研究,共614例患者随机接受TMVr联合最大耐受GDMT或单纯GDMT。
  • 采用新型超声心动图算法在筛选过程中评估二尖瓣反流严重程度,基线和随访至2年的标准化超声心动图由核心实验室分析。

主要发现

  • 基线平均左室射血分数为31.3 ± 9.3%,左室舒张末期容积为192.7 ± 71 ml,有效反流口面积为0.41 ± 0.15 cm2。
  • 随访期间两组左室射血分数下降、左室容积逐渐增加,但TMVr组变化较小(p < 0.05)。

关键数值与推荐

  • 入选标准为心衰合并中度至重度(3+)或重度(4+)继发性二尖瓣反流,并采用严格超声心动图标准筛选。

临床怎么用

  • 严格应用COAPT试验的超声心动图筛选标准,有助于将TMVr的获益转化为临床实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) trial among patients with heart failure (HF) and moderate-to-severe (3+) or severe (4+) secondary mitral regurgitation, patients treated with transcatheter mitral valve repair (TMVr) through leaflet approximation had reduced rates of HF hospitalization and mortality compared with guideline-directed medical therapy (GDMT) alone. OBJECTIVES: The purpose of this study was to describe the echocardiographic patient qualification process for the COAPT trial, baseline echocardiographic characteristics, changes over time, and the interaction between treatment group and echocardiographic parameters on clinical outcomes. METHODS: A novel echocardiographic algorithm was implemented for grading mitral regurgitation severity during the screening process. Standardized echocardiograms were obtained at baseline and during regular follow-up intervals through 2 years, and were analyzed by a core laboratory. RESULTS: A total of 614 patients were randomized to TMVr plus maximally tolerated GDMT or GDMT alone. Mean baseline left ventricular (LV) ejection fraction was 31.3 ± 9.3%, LV end-diastolic volume was 192.7 ± 71 ml, and effective regurgitant orifice area was 0.41 ± 0.15 cm2. The beneficial effect of TMVr compared with GDMT alone was consistent in all echocardiographic subgroups, independent of the severity of LV dysfunction, LV dilatation, pulmonary hypertension, severity of tricuspid regurgitation, or individual mitral regurgitation characteristics. The LV ejection fraction decreased and the LV volumes progressively increased in both groups during follow-up, although less after TMVr (p < 0.05). CONCLUSIONS: HF patients in the COAPT trial with 3+ or 4+ secondary mitral regurgitation, selected using strict echocardiographic criteria, benefitted from TMVr with reduced 2-year rates of death and HF hospitalization. Strict application of these echocardiographic criteria should enable the COAPT results to be translated to clinical practice. (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation [The COAPT Trial] [COAPT]; NCT01626079).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Asch FM, Grayburn PA, Siegel RJ, et al. Echocardiographic Outcomes After Transcatheter Leaflet Approximation in Patients With Secondary Mitral Regurgitation: The COAPT Trial. J Am Coll Cardiol. 2019. PMID: 31574303. doi:10.1016/j.jacc.2019.09.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。